Marinus Pharma (MRNS) Tops Q2 EPS by 11c

Marinus Pharma (NASDAQ: MRNS) reported Q2 EPS of ($0.61), $0.11 better than the analyst estimate of ($0.72). Revenue for the quarter came in at $6.08 million versus the consensus estimate of $5.71 million.

For earnings history and earnings-related data on Marinus Pharma (MRNS) click here.

You May Also Be Interested In

• Wolfe Research starts Ferrari at Outperform, sees 'solid upside potential'
• Raymond James Starts Park National (PRK) at Market Perform
• TRNR agrees to acquire STEPR, raises 2026 revenue guidance to $50M